SARMS (Selective Androgen Receptor Modulators) have become a topic of significant interest due to their anabolic yet seemingly side effect friendly nature. There are three SARMS that have been developed that are sold pharmaceutically or in what is known as the gray chemical research market. These three SARMS include:
The medication GW-501516 is also at times thrown into the SARM category; however, GW-501516 is not a SARM but officially a Peroxisome Proliferator-Activated Receptor Agonist (PPAR).
There are six SARMS that are still in pre-clinical stages. It is unknown how long before research is complete or if it is discontinued. These six SARMS are rarely found in any market and there is very limited information available on their effects both positive and negative. The six pre-clinical SARMS include:
The six pre-clinical SARMS, what is known about them does lend to significant possibilities. As with all SARMS the six pre-clinical SARMS are designed to attach to the androgen receptors without promoting significant activity that’s generally viewed as negative on the secondary sex organs. They function by altering the gene expression through a binding at the androgen receptors. What this means is the target areas of function for these SARMS is primarily that of muscle and bone and only muscle and bone, which is not the case with anabolic androgenic steroids.
The six pre-clinical SARMS have shown promise in many areas of treatment, which may also be beneficial to the performance enhancing athlete. This will especially hold true if side effects are relatively limited as have been with the existing SARMS already on the market. The positive benefits intended as well as some that have been unintended yet of a positive nature include:
It’s not difficult to see how potentially beneficial these pre-clinical SARMS may be in a therapeutic or medical setting. It’s also fairly easy to see how they may be beneficial to the athlete, even more so when you consider the possibility of little to no side effects of consequence. However, because of the stage of research, full side effect potential is not fully understood. You may find some information from direct user experience on internet message boards, but most of this will be opinion with little factual data to back it up.
If you are attempting to buy any of the pre-clinical SARMS you will find it’s not all that easy. Many research chemical companies sell SARMS but S4, LGD-4033 and MK 2866 will be what are commonly found. You will not find an abundant market of the pre-clinical versions until if and when GlaxoSmithKline (GSK), GTx and Ligand Pharmaceuticals complete further studies; the three representing the primary researchers and developers of SARMS and related medications with GTx being perhaps the most advanced. Buyers should beware if they come across pre-clinical SARM purchases online. While such purchases are possible, they are not common and will generally be fake.